MP
SABS icon

Mangrove Partners’s SAB Biotherapeutics SABS Stock Holding History

Mangrove Partners’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-51,838
Closed -$5.09M – 329
2021
Q1 		$5.09M Buy
+51,838
New +$5.18M 0.51% 37

Other funds holding SABS

KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return

Mangrove Partners's SABS Position: Q2 2021 in Review

Mangrove Partners sold out of SAB Biotherapeutics (SABS) in Q2 2021, closing a stake of 51,838 shares — an estimated $5.09M sold.

Mangrove Partners first reported a position in SABS in Q1 2021 and held it in 1 quarter. The position peaked at $5.09M in Q1 2021. 37 funds tracked by Wall St. Rank hold SABS as of Q2 2021.

  • Mangrove Partners reported no remaining SAB Biotherapeutics position as of Q2 2021 after selling out during the quarter.
  • Mangrove Partners sold 51,838 SAB Biotherapeutics shares in Q2 2021, an estimated $5.09M.
  • Mangrove Partners first reported a position in SAB Biotherapeutics in Q1 2021 and held it in 1 quarter.
  • Mangrove Partners's SAB Biotherapeutics position peaked at $5.09M in Q1 2021.
  • 37 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2021.

Based on Mangrove Partners's 13F filing for Q2 2021, filed 16 Aug 2021.